



National Collaborative for Innovation in Quality Measurement

Metabolic Screening for Children and Adolescents Newly on Antipsychotics

Administrative Specification

Measure Description

The percentage of children and adolescents 1 to 20 years of age newly prescribed antipsychotic medication who had metabolic screening within 90 days prior to 15 days after the new prescription was dispensed.

Note: A higher rate indicates better performance.

Definitions

Intake Period	January 1 through December 16 of the measurement year.
IPSD	Index Prescription Start Date. The earliest prescription dispensing date for an antipsychotic medication during the Intake Period and there is a Negative Medication History.
Negative Medication History	A period of 120 days (4 months) prior to the IPSD when the individual had no antipsychotic medications dispensed for either new or refill prescriptions.

Eligible Population

Ages	1 to 20 years by December 31 of the measurement year. Report four age stratifications and a total rate. <ul style="list-style-type: none">• 1-5 years• 6-11 years• 12-17 years• 18-20 years• Total.
-------------	---

The total is the sum of the age stratifications.

Continuous Enrollment	120 days (4 months) prior to the IPSD through 15 days after the IPSD.
------------------------------	---

Allowable Gap	None.
----------------------	-------

Benefits	Medical and Pharmacy.
-----------------	-----------------------

Event/ diagnosis	Follow the steps below to identify the eligible population.
-----------------------------	---

- Step 1** Identify all children and adolescents in the specified age range who were dispensed an antipsychotic medication (Table 1) during the Intake Period.
- Step 2** Test for Negative Medication History. For each individual identified in step 1, test each antipsychotic prescription for a Negative Medication History. The IPSD is the dispensing date of the earliest antipsychotic prescription in the Intake Period with a Negative Medication History.
- Step 3** Calculate continuous enrollment. Individuals must be continuously enrolled for 120 days (4 months) prior to the IPSD through 15 days after the IPSD.

Step 4 Required exclusions Exclude individuals who had an acute inpatient encounter for mental health or chemical dependency during the 90 days prior to 15 days after the IPSD. An acute inpatient encounter in combination with any of the following meets criteria:

- A principal mental health diagnosis ([Mental Health Diagnosis Value Set](#)).
- A principal diagnosis of chemical dependency ([Chemical Dependency Value Set](#)).

Numerator

Both of the following during the 106-day period from 90 days prior to the IPSD through 15 days after the IPSD.

- At least one test for blood glucose ([Glucose Tests Value Set](#)) or HbA1c ([HbA1c Tests Value Set](#)).
- At least one test for LDL-C ([LDL-C Tests Value Set](#)) or cholesterol ([Cholesterol Tests Other Than LDL Value Set](#)).

Table 1. Antipsychotic Medications

Description	Prescription
First Generation Antipsychotic Medications	<ul style="list-style-type: none"> • Chlorpromazine hcl • Fluphenazine hcl • Fluphenazine decanoate • Fluphenazine enanthate • Haloperidol • Haloperidol decanoate • Haloperidol lactate • Loxapine hcl • Loxapine succinate
Second Generation Antipsychotic Medications	<ul style="list-style-type: none"> • Molindone hcl • Perphenazine • Pimozide • Promazine hcl • Thioridazine hcl • Thiothixene • Thiothixene hcl • Trifluoperazine hcl • Triflupromazine hcl
Combinations	<ul style="list-style-type: none"> • Aripiprazole • Clozapine • Iloperidone • Olanzapine • Olanzapine pamoate • Paliperidone • Paliperidone palmitate • Quetiapine fumarate • Risperidone • Risperidone microspheres • Ziprasidone hcl • Ziprasidone mesylate
	<ul style="list-style-type: none"> • Olanzapine-fluoxetine hcl (Symbyax) • Perphenazine-amitriptyline hcl (Etrafon, Triavil [various])